Cancer Letters
Cancer Letters is an oncology journal published by Elsevier. Founded in September 1975 and now running at 28 issues a year, it carries print ISSN 0304-3835 and online ISSN 1872-7980, reports a 2025 impact factor of 11.8, and emphasises basic and translational oncology.Cancer Letters 是爱思唯尔出版的肿瘤学期刊，1975 年 9 月创刊，现为每年 28 期，印刷版编号 0304-3835、电子版编号 1872-7980，2025 年影响因子为 11.8，侧重基础与转化肿瘤学。[1]
Scope
- Scope: an international journal providing a forum for original and pertinent contributions in cancer research, considering full-length articles and mini reviews in the broad area of basic and translational oncology, with a focus on experimental therapeutics and targeted therapies for personalised cancer medicine.学科定位： 国际性癌症研究期刊，为基础与转化肿瘤学提供原创成果交流平台，重点在实验治疗学，尤其个性化癌症医疗的靶向治疗。[2]
- Topics: molecular genetics and cell biology of cancer, radiobiology, molecular pathology, hormones and cancer, viral oncology, metastasis, chemoprevention, and experimental therapeutics including targeted therapy and metronomic chemotherapy.收录主题： 癌症分子遗传学与细胞生物学，放射生物学，分子病理学，激素与癌症，病毒肿瘤学，转移，化学预防，以及实验治疗学与靶向治疗含节拍化疗。
- Article types: original research articles, reviews, mini reviews and research letters, letters to the editor and editorials, each with explicit word and reference limits.文章体裁： 原创研究论文、综述、短综述与研究通讯、致编辑信与社论，各体裁有明确词数与参考文献数上限。
- Publishing model: hybrid open access, with authors choosing between an open access route carrying an article processing charge and a subscription route free of publication charges.出版模式： 混合开放获取，作者可选开放获取或订阅路径，开放获取需支付版面费。
- Indexing and metrics: covered by the SCIE, PubMed and Scopus, with a 2025 impact factor of 11.8 and a CiteScore of 15.4.收录与指标： 被 SCIE、PubMed 与 Scopus 收录，2025 年影响因子 11.8、CiteScore 15.4。
History
- Founded: the journal was founded in September 1975 by Elsevier and North-Holland of Amsterdam, and has been indexed in MEDLINE since its first issue.创刊： 1975 年 9 月由阿姆斯特丹的爱思唯尔与北荷兰出版社创刊，自创刊号起被 MEDLINE 收录。[3]
- Expansion of frequency: launched as a monthly, the journal grew to 26 issues a year and now runs at 28, with each year from 2023 to 2025 comprising 28 volumes.刊期扩张： 创刊初期为月刊，其后逐步增至每年 26 期，现为每年 28 期，2023 至 2025 年各年均为 28 卷。[4]
- Title history: no renaming on record, the title Cancer Letters has been in use since 1975.更名史： 无更名记录，创刊至今沿用 Cancer Letters 刊名。
Editors
- Editor-in-chief: Min Li, of the University of Oklahoma Health Sciences Center in the United States.现任主编： Min Li，美国俄克拉何马大学健康科学中心。[5]
- Senior editor: Webster Cavenee, PhD, of the School of Medicine at the University of California San Diego in the United States.资深编辑： Webster Cavenee，哲学博士，美国加利福尼亚大学圣迭戈分校医学院。
- Editorial board: the official editorial board page counts 88 editors and editorial board members across 15 countries and regions, with 36 from the United States and 27 from China.编委构成： 官方编委页统计共 88 名编辑与编委成员，分布于 15 个国家与地区，其中美国 36 人、中国 27 人。
- Submission and review: submissions go through Editorial Manager under single anonymized review, typically with at least two reviewers, and regular manuscripts require no pre-submission enquiry.投稿与评审： 经 Editorial Manager 系统投稿，实行单盲评审，通常至少送 2 名审稿人，常规稿件无需投稿前询稿。
- Place of publication: the journal is now issued by Elsevier Ireland, having been founded in the Netherlands.出版地： 现刊由爱尔兰的爱思唯尔公司出版，创刊地在荷兰。